In Vitro Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness In Vivo.

Adoptive T-cell transfer therapy is an FDA- approved treatment for leukemia that relies on the ex vivo expansion and reinfusion of a patient's immune cells, which can be engineered with a chimeric antigen receptor (CAR) for more efficient tumor recognition. Type 17 T cells, controlled transcriptionally by RORγ, have been reported to mediate potent antitumor effects superior to those observed with conventionally expanded T cells. Here, we demonstrate that addition of a synthetic, small-molecule RORγ agonist during ex vivo expansion potentiates the antitumor activity of human Th17 and Tc17 cells redirected with a CAR. Likewise, ex vivo use of this agonist bolstered the antitumor properties of murine tumor-specific CD4+ and CD8+ T cells. Expansion in the presence of the RORγ agonist enhanced IL17A production without compromising IFNγ secretion in vitroIn vivo, cytokine neutralization studies revealed that IFNγ and IL17A were required to regress murine melanoma tumors. The enhanced antitumor effect of RORγ agonist treatment was associated with recovery of more donor T cells in the tumor and spleen; these cells produced elevated levels of cytokines months after infusion and expressed markers of long-lived stem and central memory cells such as Tcf7 and CD62L. Conversely, untreated cells mainly exhibited effector phenotypes in the tumor. Cured mice previously treated with agonist-primed T cells were protected from tumor rechallenge. Collectively, our work reveals that in vitro treatment with a RORγ agonist generates potent antitumor Type 17 effector cells that persist as long-lived memory cells in vivoSignificance: RORγ agonists can be used in vitro during T-cell expansion to enhance the efficacy of adoptive cell therapy (e.g., CAR-T) and to provide long-term protection against tumors.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/14/3888/F1.large.jpg Cancer Res; 78(14); 3888-98. ©2018 AACR.

[1]  B. Becher,et al.  High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy , 2018, Nature Medicine.

[2]  S. Grupp,et al.  Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. , 2017, Blood.

[3]  W. Miller,et al.  Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. , 2017, The New England journal of medicine.

[4]  A. Bhandoola,et al.  CD8+ T Lymphocyte Self-Renewal during Effector Cell Determination. , 2016, Cell reports.

[5]  P. Toogood,et al.  Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity , 2016, Oncoimmunology.

[6]  P. Toogood,et al.  Sterol metabolism controls T(H)17 differentiation by generating endogenous RORγ agonists. , 2015, Nature chemical biology.

[7]  Mark S. Sundrud,et al.  Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. , 2015, Cancer research.

[8]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[9]  M. Karin,et al.  Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. , 2014, Immunity.

[10]  Matthew J. Frigault,et al.  ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. , 2014, Blood.

[11]  S. Mehrotra,et al.  Th17 Cells in Cancer: The Ultimate Identity Crisis , 2014, Front. Immunol..

[12]  C. Creighton,et al.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.

[13]  B. Fox,et al.  Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells , 2013, European journal of immunology.

[14]  P. Muranski,et al.  Essentials of Th17 cell commitment and plasticity. , 2013, Blood.

[15]  R. Danner,et al.  Th17 cells are long lived and retain a stem cell-like molecular signature. , 2011, Immunity.

[16]  J. Moyer,et al.  Human TH17 Cells Are Long-Lived Effector Memory Cells , 2011, Science Translational Medicine.

[17]  C. June,et al.  The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells , 2010, Science Translational Medicine.

[18]  S. Rosenberg,et al.  CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma , 2010, Clinical Cancer Research.

[19]  F. Nestle,et al.  Faculty Opinions recommendation of Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. , 2010 .

[20]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[21]  P. Hwu,et al.  T helper 17 cells promote cytotoxic T cell activation in tumor immunity. , 2009, Immunity.

[22]  Annaïg Lan,et al.  The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. , 2009, Immunity.

[23]  M. Banerjee,et al.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. , 2009, Blood.

[24]  P. Muranski,et al.  Type 17 CD8+ T cells display enhanced antitumor immunity. , 2009, Blood.

[25]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[26]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[27]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[28]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[29]  H. Spits,et al.  Human fetal lymphoid tissue–inducer cells are interleukin 17–producing precursors to RORC+ CD127+ natural killer–like cells , 2009, Nature Immunology.

[30]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.

[31]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .